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http://dx.doi.org/10.1016/j.chembiol.2012.10.006The gooey stream of fat that plastic
surgeons pull from pudgy tummies and
thighs during liposuction may one day
treat a host of medical conditions. Fat
(or adipose tissue) actually contains
stem cells that can differentiate into
many cell types. Like stem cells from
other sources, adipose stem cells (or
ASC) take on the characteristics of the
surrounding environment. Such flexibility
means that fat stem cells hold the poten-
tial to treat a broad range of diseases
and conditions.
Liposuction is an office procedure and
is a less painful and less involved proce-
dure than aspirating stem cells from
bone marrow; it yields more stem cells,
as well. Like bone marrow cells, fat stem
cells come from adult tissues and there-
fore do not carry the moral and ethicalToday, adipose stem cells are a hot topic in tissue engineering.baggage surrounding the use of embry-
onic stem cells.
‘‘Let’s face it, nobody is emotionally
attached to their fat,’’ says John W. Lu-
dlow, Ph.D., executive director at ZenBio,
Inc., in Research Triangle Park, North
Carolina. ZenBio processes and supplies
ASC for in vivo and in vitro studies.
Fat Chance
Researchers always suspected that fat
contained precursor cells that differenti-
ated into adipocytes when the call came
to produce fat. By the late 1990s and early
2000s, researchers began to discover—
via different routes—that preadipocytes
were actually stem cells that could differ-
entiate into many cell types.
In 2003, Jeffrey Gimble, M.D., Ph.D, of
the Pennington Biomedical Research
Center, Baton Rouge, Louisiana, pub-
lished a review suggesting that adipose
stem cells can be used for ‘‘applications
in tissue engineering and regenerative
medicine’’ once certain culture conditions
could beworkedout. Gimble’s reviewalsoraised the question of whether ASCs
would be used only for self (or autologous)
donation or whether such cells could be
used as donor tissue for others (allogeneic
donation) without worry of rejection or
use of antirejection drugs, (Gimble, 2003).
Today, adipose stem cells are a hot
topic in tissue engineering. A check at
the National Institutes of Health website
(http://clinicaltrials.gov) using the search
terms ‘‘adipose stem cells’’ lists 80 clinical
trials for applications including osteoar-
thritis, type I and type II diabetes, and
grafts for breast reconstruction following
cancer or trauma. Gimble credits the
rapid progress in the ASC field to the
fact that ASC research has become an
international endeavor.
Techniques to culture ASC are
fairly straightforward today. In general,following liposuction, the cells need to
be processed by digestion with enzymes,
washed to get rid of blood and extraneous
tissue, and then cultured. Not all
researchers use the same techniques.
Some take the cells from liposuction and
enrich the stromal population through
adherence to plastic, which enriches
a viable cell population and simplifies
the technique by not introducing other
variables, such as the presence of anti-
bodies, says Gimble. In contrast, some
researchers use an antibody specifically
aimed against a particular surface pro-
tein to pull a defined population from
the heterogeneous mix of cells contained
in fat.
The adherence method yields a range
between 100,000 and 300,000 cells from
one milliliter of liposuction aspirate. After
cells are cultured on plastic, yields can
reach one million cells. Some liposuction
donors shed a liter or more of aspirate
per donation. Adipose tissue yields from
100 to 1000 times more cells per unit
volume than bone marrow. ‘‘UltimatelyChemistry & Biology 19, October 26, 2012 ª[the chosen technique] will come down
to what is the cell function in vivo. We
still need to address how well the cells
respond to the environment after further
manipulation andwhether you get enough
cells to give you what you need,’’ says
Gimble.
In 1996, Gimble and colleagues
founded Artecel, Inc., in Bethesda,
Maryland, as a provider of ASC. In 2003,
Toucan Capital, a stem cell investment
group, purchased Artecel. More recently,
Gimble founded LaCell LLC located in
Baton Rouge, Louisiana, which received
SBIR funding in 2012 to study the poten-
tial of ASCs in wound healing in an aging
model of pressure ulcers. LaCell will also
provide high quality cells from ASC and
other tissues to researchers.
Enriching Yield
Fat contains a mix of differentiated cells
such as macrophages and mesenchymal
cells in addition to stem cell populations
with unique cell-surface markers. Sorting
through the basic biology of this mix
will help researchers figure out whether,
for example, manipulating the mix by
enriching one subtype of stem cell over
another could be the best way to treat
certain diseases. First, researchers need
to understand whether harvesting tech-
niques damage certain subtypes of ASC,
says William Zamboni, M.D., professor
and chairman of the department of
surgery at the University of Nevada
School of Medicine.
Zamboni’s group has an IRB-approved
human study harvesting fat cells via
standard liposuction from adults. His
team then examines whether particular
populations of fat stem cells are more
prone to apoptosis (programmed cell
death) during harvesting, centrifugation,
refrigeration, freezing, or even canula
size from liposuction. The team has been
working on several projects compar-
ing the rate of apoptosis and necrosis
among the specific subtypes of fat
stem stems as they are processed in
the lab following liposuction. Preliminary2012 Elsevier Ltd All rights reserved 1211
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tent of cell death varies among different
subpopulations.
‘‘What we’re saying is that we’re not
lumping all of the stem cells together. A
stem cell is not a stem cell. The whole
idea is increasing viability through harvest
techniques,’’ Zamboni says.
Breaching Regulatory Hurdles
The ASC in clinical trials are being tested
for self-donation. Some animal studies
suggest that ASCs are what is referred
to as ‘‘immune privileged.’’ The immune
system can tolerate an allogenic dona-
tion, that is, adipose stem cells from
a different donor, but that technique has
not yet reached the point of human clinical
trials.
For ASC to find reach the clinic, the
greatest hurdle going forward will likely
be regulatory, says Ludlow of ZenBio.
Stem cell usage for therapies is one of
the more highly scrutinized approaches
in cell therapy by the FDA and other
regulatory agencies, explains Ludlow.
‘‘With any stem cell therapy, we need
to be absolutely certain that the cells
being placed into the body are going to
be the cells that you want them to be
and not something aberrant like cancer,’’
he says.
Because stem cells are highly influ-
enced by their local environment, if they
are placed in an area of the body that
contains a lot of aberrant, or cancer cells,
you’ll run a greater risk that they can
become abnormal themselves. ‘‘At what
level is it safe for the patient to have
a stem cell become aberrant—is it one
in a million, one in ten million, one in
a billion,’’ Ludlow wonders. Researchers
don’t yet know whether the aberrant
cell problem is an issue of terminal differ-
entiation, whether ASC that head down
the pathway to cardiac, smooth, or
muscle cells actually remain that type of1212 Chemistry & Biology 19, October 26, 20cell or whether an isolated population of
fat stem cells is contaminated with
‘‘rogue’’ stem cells that scientists don’t
yet know how switch off. ‘‘Cancer cells
have many of the same characteristics
as normal stem cells,’’ says Ludlow.
These issues are still being debated
and it is most likely a combination of
the two: dedifferentiation and rouge cells
can contribute to an aberrant cell popu-
lation, he says.
Rebuilding Damaged Joints
Other technical challenges loom. Once
researchers can work out whether ASC
can be used in allogeneic donations,
companies like ZenBio and Cytex Thera-
peutics can operate much like blood
banks, pulling a vial of cells off the shelf
that’s been prescreened and is ready for
use, says Farshid Guilak, Ph.D., of Duke
University. Guilak’s team is developing
cell-based scaffold therapies for osteoar-
thritis (OA) using stem cells from bone
marrow and fat.
In 2006, Guilak and partners founded
Cytex Therapeutics, an early stage start
up primarily funded with SBIR grants
from the NIH. The aim of the company
is to develop different therapies for OA
and cartilage repair using scaffolds and
stem cells from bone marrow and fat.
Aging, injuries, and wear and tear
destroy cartilage. Over time, this damage
leads to end-stage joint disease, the point
at which knees, hips, or finger joints need
to be replaced. Like potholes, these
defects begin as tiny chinks and deepen
over time. Most cell-based research is
focused on fixing these small defects.
Guilak’s team aims to repave the whole
road. In one strategy, Guilak cultures
ASC or bone marrow stem cells on a
scaffold biomaterial that mimics the
strength and biomechanical properties
of cartilage. The idea is to cover the entire
joint with this cell-enriched scaffold,12 ª2012 Elsevier Ltd All rights reservedwhich can cushion the joint while the cells
laced through the biomaterial have time
to regenerate the body’s natural cartilage.
Treating end stage osteoarthritis with
a biological approach that preserves
the joint may stave off the need for
total joint replacement, an impermanent
solution that lasts about a decade or so.
‘‘If we can put that off for 10 years
with a biological resurfacing, it would
have a lot of advantages for younger
people with osteoarthritis, which is getting
more common with injuries, obesity, and
other factors,’’ says Guilak.
His team also conducts research on
how obesity affects joints and the pro-
gression to osteoarthritis. They’re also
using stem cells as in vitro models of dis-
ease. Laboratory-grown cartilage from
ASCs can be grown abundantly enough
to provide a vehicle for research or drug
discovery. What’s more, this cartilage
can be made patient specific, for
example, from people with different ge-
netic backgrounds or from people with
certain risk factors for diseases such
as osteoarthritis, and can be used by
pharmaceutical companies for drug dis-
covery, says Guilak.
Another challenge, says Guilak, is
getting cells to grow and regenerate fast
enough and finding the best growth
factors that accelerate development of
laboratory cartilage most quickly, and
one that regulatory bodies will accept for
translation to the clinic in an expedient
manner.
‘‘In the laboratory everything works
great,’’ Guilak says. ‘‘It’s still a long time
to reach patients.’’
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